HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Guest Access | Sign In via User Name/Password

This Article Full Text Free Full Text (PDF) Free Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (16) Citing Articles via Google Scholar Google Scholar Articles by Chrousos, G. P. Articles by Harris, A. G. Search for Related Content PubMed PubMed Citation Articles by Chrousos, G. P. Articles by Harris, A. G.

Effects of Mometasone Furoate Dry Powder Inhaler and Beclomethasone Dipropionate Hydrofluoroalkane and Chlorofluorocarbon on the Hypothalamic-Pituitary-Adrenal Axis in Asthmatic Subjects^*

^* From the First Department of Pediatrics, Athens University Medical School, Children’s Hospital "Agia Sophia," Athens, Greece; and Integrated Therapeutics Group, Kenilworth, NJ.

Correspondence to: George P. Chrousos, MD, First Department of Pediatrics, Athens University Medical School, Children’s Hospital "Agia Sophia," 11527 Athens, Greece; e-mail: chrousge{at}med.uoa.gr

Study objectives: Mometasone furoate dry powder inhaler (MF-DPI) [400 µg] is an inhaled corticosteroid (ICS) that is effective in the treatment of asthma. MF-DPI has a low potential for suppression of the hypothalamic-pituitary-adrenal (HPA) axis at its clinical dose. The effect of MF-DPI, 400 µg qd, on the HPA axis was compared to that of beclomethasone dipropionate (BDP) using hydrofluoroalkane (HFA) and chlorofluorocarbon (CFC) propellants via metered-dose inhalers (MDIs) twice daily.

Design and interventions: This randomized, third-party blind, parallel-group study compared the effects of MF-DPI 400 µg one puff qd in the morning (n = 18), HFA-BDP 200 µg two puffs MDI bid (n = 18), and CFC-BDP 400 µg two puffs MDI bid (n = 17) for 14 days on the area under the 24-h serum cortisol concentrations curve (AUC_0–24) and on total 24-h urinary free cortisol excretion in mild asthmatic subjects. Effects on morning/evening peak expiratory flow (PEF) and on inhaled albuterol use were also assessed. Adverse events that occurred during or 30 days after the study were recorded.

Results: The mean decrease from baseline in the serum cortisol concentrations AUC_0–24 in the MF-DPI group was significantly less than in either the HFA-BDP (p = 0.024) or the CFC-BDP (p = 0.011) groups. Decreases in serum cortisol concentrations AUC_0–24 in the two BDP groups did not differ from one another. The MF-DPI group trended toward higher morning and evening PEF than either BDP group. Treatment-associated adverse events were reported by seven subjects in the MF-DPI group, vs one subject in the HFA-BDP and three subjects in the CFC-BDP groups; these were mild, and no subject discontinued treatment due to an adverse event.

Conclusions: Fourteen days of treatment with MF-DPI 400 µg qd was associated with a significantly lesser decrease in the serum cortisol concentrations AUC_0–24 compared with HFA-BDP 200 µg MDI or CFC-BDP 400 µg MDI bid.

Key Words: asthma, beclomethasone dipropionate • corticosteroid • hypothalamo-hypophyseal system • mometasone furoate

This article has been cited by other articles:

				C. Leach, P. LeSouef, G. P. Chrousos, L. Ghaly, D. Iezzoni, A. Shedden, and A. G. Harris Mometasone and Beclomethasone Comparison Article Observations Chest, May 1, 2006; 129(5): 1389 - 1391. [Full Text] [PDF]